Affymax receives positive review for Phase III anemia program
The committee has informed the company that the cumulative safety data generated thus far from the Emerald and Pearl Phase III trials support continuation of the studies. In
Vertex has signed a definitive agreement to purchase Crinetics Pharmaceuticals in a transaction valued at nearly $10bn, or $8.8bn net of estimated cash acquired.
The study demonstrated that Chrysalin extensively decreases myocardial injury when administered following a major ischemic insult. Endpoints of the study included infarct size, coronary microvessel function, myocardial function